{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:16:57Z","timestamp":1767871017812,"version":"3.49.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a highly promising immunotherapy for cancer treatment. Intensive research is being conducted focusing on adverse effects that CAR-T infusions may have due to the development of cytokine release syndrome (CRS). We aim to highlight a noteworthy case of ventricular tachycardia presented in the setting of acute non-ischemic cardiomyopathy following CRS after CAR-T therapy, along with providing a detailed discussion of subsequent inpatient and outpatient management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 78-year-old man with a past medical history of prostate adenocarcinoma, hypertension, and type two diabetes mellitus, with no prior cardiac history or heart failure, underwent CAR-T therapy for diffuse large B-cell lymphoma (DLBCL). During the same hospitalization, he developed grade one CRS along with asymptomatic non-sustained ventricular tachycardia which was suspected to be bundle branch reentrant tachycardia (BBRT-VT). An echocardiogram performed after CAR-T infusion revealed a reduced left ventricular ejection fraction (LVEF) of 35%, a significant decline from his baseline LVEF of 51% two months prior. After the development of the ventricular tachyarrhythmia, amiodarone was initiated for rhythm control. However, over the subsequent five months, the patient had multiple hospital admissions for heart failure exacerbations. During this period, his EF declined to 15% when he was referred for implantable cardioverter defibrillator (ICD) implantation before gradually improving with continued amiodarone and guideline-directed medical therapy. Over the next 18 months, his LVEF recovered to 55%, highlighting the potential reversibility of immunotherapy-induced cardiomyopathy complicated by ventricular tachyarrhythmia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case showcases a prolonged cardiac recovery following complications of CAR-T therapy. It also provides insight into the successful clinical management of a patient due to CAR-T-induced cardiomyopathy in the setting of potentially complex ventricular arrhythmias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1608404","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:36:28Z","timestamp":1767854188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case of heart failure recovery after non-ischemic cardiomyopathy following chimeric antigen receptor T-cell therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"G.","family":"Spears","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Henson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vellanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Trikannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Paydak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy\u2013associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1016\/j.jacc.2017.10.030","article-title":"Catheter ablation of ventricular tachycardia in structural heart disease: indications, strategies, and outcomes\u2014part II","volume":"70","author":"Dukkipati","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.hrthm.2008.02.036","article-title":"Catheter ablation of bundle branch reentrant ventricular tachycardia","volume":"5","author":"Balasundaram","year":"2008","journal-title":"Heart Rhythm"},{"key":"B13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/pace.13018","article-title":"Atypical surface ECG complicating the diagnosis of bundle branch reentry tachycardia","volume":"40","author":"Reithmann","year":"2017","journal-title":"Pacing Clin Electrophysiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1186\/s12885-021-08823-3","article-title":"Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol","volume":"21","author":"Merino","year":"2021","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1161\/CIR.0000000000000628","article-title":"2018 ACC\/AHA\/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"140","author":"Kusumoto","year":"2019","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.echo.2012.09.001","article-title":"Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know?","volume":"25","author":"Oreto","year":"2012","journal-title":"J Am Soc Echocardiogr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"suac121.116","DOI":"10.1093\/eurheartjsupp\/suac121.116","article-title":"383 takotsubo syndrome after car-T cell infusion","volume":"24","author":"Bastianoni","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3389\/fimmu.2020.01648","article-title":"Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper","volume":"11","author":"Bhaskar","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.31579\/IJBR-2021\/027","article-title":"Cytokine storm manifesting as myocarditis as A sequela of COVID-19","volume":"1","author":"Desai","year":"2021","journal-title":"Int J Biomed Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.3390\/cells9112508","article-title":"Cardiovascular manifestations of COVID-19 infection","volume":"9","author":"Magadum","year":"2020","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fimmu.2021.589095","article-title":"Cytokine storm: the primary determinant for the pathophysiological evolution of COVID-19 deterioration","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa188","article-title":"Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report","volume":"4","author":"Chitturi","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: a report of the American College of Cardiology solution set oversight committee","volume":"85","author":"Drazner","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"691064","DOI":"10.3389\/fonc.2021.691064","article-title":"An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: a single-centre retrospective study","volume":"11","author":"Qi","year":"2021","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1046\/j.1540-8167.2002.01233.x","article-title":"Bundle branch reentrant tachycardia in patients with apparent normal His-Purkinje conduction: the role of functional conduction impairment","volume":"13","author":"Li","year":"2002","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.hrthm.2018.10.028","article-title":"Evaluation and management of ventricular tachycardia in patients with dilated cardiomyopathy","volume":"16","author":"Ebert","year":"2019","journal-title":"Heart Rhythm"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.hrthm.2025.02.044","article-title":"Mechanisms of ventricular tachycardias with a 1:1 His-V relation in patients with heart disease","volume":"22","author":"Uetake","year":"2025","journal-title":"Heart Rhythm"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.hrthm.2019.03.002","article-title":"2019 HRS\/EHRA\/APHRS\/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias","volume":"17","author":"Cronin","year":"2020","journal-title":"Heart Rhythm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/eurheartj\/ehs007","article-title":"Catheter ablation of ventricular tachycardia in ischaemic and non-ischaemic cardiomyopathy: where are we today? A clinical review","volume":"33","author":"Wissner","year":"2012","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e004494","DOI":"10.1161\/CIRCEP.116.004494","article-title":"Ventricular tachycardia ablation in severe heart failure","volume":"10","author":"Tzou","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/joim.13487","article-title":"Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction","volume":"292","author":"De Marzo","year":"2022","journal-title":"J Intern Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","article-title":"Cardiotoxic effects following CAR-T cell therapy: a literature review","volume":"27","author":"Joseph","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/ejh.14088","article-title":"Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy","volume":"112","author":"Patel","year":"2024","journal-title":"Eur J Haematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms23158242","article-title":"Cardiotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy: pathophysiology, clinical implications, and echocardiographic assessment","volume":"23","author":"Nenna","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1608404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:36:29Z","timestamp":1767854189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1608404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2025.1608404"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1608404","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1608404"}}